


# CRN: SWP uro-oncology subspecialty lead

Dr Mohini Varughese  
Consultant Clinical Oncologist  
Beacon Centre, Musgrove Park Hospital  
Taunton

# Cancer – SWP Sub-Specialty Recruitment Summary


Sub-Specialty Group	2008/2009	2009/2010	2010/2011	2011/2012	2012/2013	2013/2014	2014/2015	2015/2016	2016/2017
All Sub-Specialties (migration)		55	40						
Biomarkers and imaging								7	13
Brain		1	2	3	2	19	25	24	22
Breast	492	644	766	610	722	865	320	366	281
Colorectal	169	487	235	418	205	97	72	97	81
Gynae	26	123	170	80	57	62	106	79	73
Haematology	146	173	240	240	240	250	277	218	206
Head and neck	4	69	39	84	27	48	57	12	12
Lung	63	85	68	78	57	51	49	27	82
Palliative and supportive care			70	36	7	22	100	156	14
Primary care									
Psychosocial oncology							5	1	
Radiotherapy									
Sarcoma		2	3		5	10			6
Skin cancer	9	11	25	18	19	45	23	6	7
Upper GI	106	111	164	109	31	76	123	126	74
Urology	185	199	190	146	164	230	394	479	402
Young People					14	29	14	4	1
<b>Grand Total</b>	<b>1200</b>	<b>1960</b>	<b>2012</b>	<b>1822</b>	<b>1550</b>	<b>1804</b>	<b>1565</b>	<b>1602</b>	<b>1274</b>

# SWP Urology Group Recruitment



Highest recruiting subspecialty in the CRN;SWP (25 & 29% of all oncology recruitment vs 18.3 & 24.9% nationally)


# Urology Group National Perspective




# Urology Group National Perspective

CRN	2015/2016			2016/2017		
	Recruitment	Rank	Adj. for Pop. Rank	Recruitment	Rank	Adj. for Pop. Rank
East Midlands	376	12	<b>15</b>	330	13	<b>14</b>
Eastern	704	5	<b>5</b>	804	5	<b>8</b>
Greater Manchester	394	11	<b>10</b>	1042	2	<b>1</b>
Kent, Surrey and Sussex	906	3	<b>4</b>	1058	1	<b>5</b>
North East and North Cumbria	552	8	<b>6</b>	1002	4	<b>2</b>
North Thames	850	4	<b>8</b>	1011	3	<b>9</b>
North West Coast	473	10	<b>11</b>	220	15	<b>15</b>
North West London	200	15	<b>14</b>	583	10	<b>3</b>
South London	1083	1	<b>1</b>	687	6	<b>7</b>
South West Peninsula	479	9	<b>3</b>	402	12	<b>10</b>
Thames Valley and South Midlands	628	7	<b>2</b>	626	7	<b>4</b>
Wessex	371	13	<b>9</b>	590	9	<b>6</b>
West Midlands	679	6	<b>12</b>	618	8	<b>11</b>
West of England	257	14	<b>13</b>	243	14	<b>12</b>
Yorkshire and Humber	965	2	<b>7</b>	539	11	<b>13</b>

# Urology Group SWP Recruitment



# Not just one trial for each disease; a trial for each stage of disease

Location: Dept of Oncology & Palliative Care Taunton and Somerset   
NHS Foundation Trust

Clinic date: 19 Jan 2017  
Transcribed by: HY - 24 Jan 2017  
NHS No:  
Hospital No:

Consultant: Dr. J. Graham  
Dept of Oncology & Palliative Care  
Musgrove Park Hospital  
Taunton  
Somerset  
TA1 5DA

Dr.  
General Practitioner  
Wellington Medical Centre  
Mantle Street  
Wellington  
Somerset  
TA21 8BD

Secretary direct line: 01823 342417  
Fax: 01823 342419

Dear Dr

**Diagnosis:**  
Castrate-resistant metastatic adenocarcinoma of the prostate (spinal and pelvic bone metastases)

**Treatment:**  
2012 Laparoscopic radical prostatectomy  
Post-op radiotherapy in **RADICALS** trial completed April 2013  
May 2014 - PSA 4.31 and bone metastases on scan - started hormone therapy  
August 2014, patient enrolled in the **STAMPEDE** trial. Allocated LHRH agonist alone. PSA 1.67  
September 2015, 8Gy palliative radiotherapy to the left ileum  
January 2016, PSA rise to 5.06 (alkaline phosphatase 535), bicalutamide added for maximum androgen blockade  
May 2016 - commenced Enzalutamide  
January 2017 - progressive disease with rising PSA and increasing bone pain  
Stop Enzalutamide and start Docetaxel chemotherapy

Pt also enrolled within RAPPER, PREMISE and PROMPTS

# CRN: SWP Uro oncology

- Key is balancing the portfolio
- Achieving equal access for all
- Reviewing estimated targets



Acronym	Local Acronym	UKCRN ID	Division	Specialty	Commercial Study	Trust	Investigator Name	Project Site Status	Local Trust Approval / Date of HRA Approval	End Date of Recruitment Phase	Participant Recruitment Target	Recruitment (EDGE)	recruitment 2016/17 (EDGE)	Recruitment (Portfolio)	RTT	Project Site Type	Comments
CALIBER		17640	Division 1	Bladder Cancer	No	PHNT	Hunter Campbell, Mr Paul	Open	11/04/2016	27/04/2017	3	0	0	0	-87	Recruiting Site	Nationally this study is amber having recruited 61 out of a target of 164. Study close date now 28/2/18 - to be updated on edge by site. Site have been contacted about re-evaluation of target and research nurse to discuss with PI. Lead Nurse at PHNT has also met with team and plan is being put in place to focus attention on this trial now that HIVEC II has exceeded target.
CALIBER		17640	Division 1	Bladder Cancer	No	RDEFT	McGrath, Mr John	Open	24/02/2015	28/02/2018	7	5	0	5	4	Recruiting Site	
DETECT I		30434	Division 1	Bladder Cancer	No	NDHT	Ong, Mr Eng	Open	17/08/2016	31/03/2017	80	89	89	75	22	Recruiting Site	
DETECT I		30434	Division 1	Bladder Cancer	No	PHNT	Natale, Mr Salvatore	Open	30/11/2016	31/10/2017	400	71	71	59	-11	Recruiting Site	
DETECT I		30434	Division 1	Bladder Cancer	No	RCHT	Maclean, Miss Kirsty	Open	23/12/2016	01/02/2019	30	20	20	0	57	Recruiting Site	
Hyperthermia for Intermediate risk bladder cancer (HIVEC-II)		15853	Division 1	Bladder Cancer	No	PHNT	Hunter Campbell, Mr Paul	Open	21/11/2014	01/10/2017	10	19	5	19	110	Recruiting Site	
JAVA-P		17390	Division 1	Bladder Cancer	No	RCHT	Thomson, Dr Alastair	Open	01/03/2016	30/11/2016	1	1	1	0	-36	Recruiting Site	
POUT		11494	Division 1	Bladder Cancer	No	NDHT	Sheehan, Dr Denise	Open	05/03/2012	31/03/2019	5	5	1	5	29	Recruiting Site	
POUT		11494	Division 1	Bladder Cancer	No	RCHT	Wheatley, Dr Duncan	Open	24/01/2013	31/03/2019	5	4	1	4	13	Recruiting Site	
POUT		11494	Division 1	Bladder Cancer	No	RDEFT	Sheehan, Dr Denise	Open	07/09/2012	31/03/2019	5	3	1	3	-9	Recruiting Site	
POUT		11494	Division 1	Bladder Cancer	No	TSFT	Varughese, Dr Mohini	Open	01/10/2012	31/03/2019	4	2	0	2	-18	Recruiting Site	Nationally this study is close to achieving target, site are aware. Site are currently happy to stick with target of 4 as feel this is achievable within the current timescale.
POUT		11494	Division 1	Bladder Cancer	No	TSDFT	Lydon, Dr Anna	Open	03/06/2013	31/03/2019	3	4	1	3	69	Recruiting Site	
RAIDER		18868	Division 1	Bladder Cancer	No	TSFT	Varughese, Dr Mohini	Open	04/02/2016	01/11/2017	2	6	5	6	238	Recruiting Site	
The PHOTO Trial		17055	Division 1	Bladder Cancer	No	RDEFT	McGrath, Mr John	Open	27/11/2014	28/02/2017	20	49	11	49	144	Recruiting Site	This study is flagging red nationally at 77% of target with only 2 months left to recruit, RD&E are highest recruiting Trust in UK. Sponsor contacted regarding 'end of recruitment' date and over-recruitment by RD&E. SPONSOR have confirmed that they are happy with the levels of over-recruitment as they are still short of target by 160 patients and have exceeded until 31/03/17



DASHBOARD

Business Intelligence Unit

Cancer Portfolio Maps

- NIHR CRN SWP Breast Research Portfolio Map
- NIHR CRN SWP Colorectal/Research Portfolio Map
- NIHR CRN SWP Gynae-Oncology Research Portfolio Map
- NIHR CRN SWP Head & Neck Research Portfolio Map
- NIHR CRN SWP Lung Research Portfolio Map
- NIHR CRN SWP Lymphoma Research Portfolio Map
- NIHR CRN SWP Malignant Haematology Research Portfolio Map
- NIHR CRN SWP Non Malignant Haematology Research Portfolio Map
- NIHR CRN SWP Upper GI Research Portfolio Map
- NIHR CRN SWP Urology Research Portfolio Map**

Monthly Reports

Business Intelligence Unit > Cancer Portfolio Maps >

# NIHR CRN SWP Urology Research Portfolio Map

	NDHT	PHNT	RCHT	RDEFT	TSFT	TSDFE	YDH
<b>PROSTATE continued</b>							
<b>Localised</b>				CARC 4500 EMBARK (PI Denise Sheehan)			
<b>Localised</b>	Add Aspirin (PI Denise Sheehan)	Add Aspirin (PI Sid Dubey)	Add Aspirin (PI Duncan Wheatley)	Add Aspirin (PI Anne Hong)	Add Aspirin (PI Mohini Varughese)	Add Aspirin (PI Nangi Lo)	Add Aspirin (PI Matthew Sephton)
<b>Localised</b>	RADICALS (PI Denise Sheehan)		RADICALS - MRC PR10 (PI Duncan Wheatley)	RADICALS - MRC PR10 (PI Rajaguru Srinivasan)	RADICALS - MRC PR10 (PI Mohini Varughese)	RADICALS MRC PR10 (PI Anna Lydon)	RADICALS - MRC PR10 (PI Erica Beaumont)
<b>Locally advanced</b>	Add Aspirin (PI Denise Sheehan)	Add Aspirin (PI Sid Dubey)	Add Aspirin (PI Duncan Wheatley)	Add Aspirin (PI Anne Hong)	Add Aspirin (PI Mohini Varughese)	Add Aspirin (PI Nangi Lo)	Add Aspirin (PI Matthew Sephton)
<b>Locally advanced</b>	RADICALS - MRC PR10 (PI Denise Sheehan)		RADICALS - MRC PR10 (PI Duncan Wheatley)	RADICALS - MRC PR10 (PI Rajaguru Srinivasan)	RADICALS - MRC PR10 (PI Mohini Varughese)	RADICALS MRC PR10 (PI Anna Lydon)	RADICALS - MRC PR10 (PI Erica Beaumont)
<b>Locally advanced</b>	Stampede (PI Denise Sheehan)			Stampede (PI Denise Sheehan)	Stampede (PI John Graham)	Stampede (PI Nangi Lo)	Stampede (PI Geoff Sparrow)
<b>Locally advanced</b>		CANC 4742 ATLAS (PI Sarah Pascoe)					
<b>Metastatic - hormone sensitive</b>	Stampede (PI Denise Sheehan)			Stampede (PI Denise Sheehan)	Stampede (PI John Graham)	Stampede (PI Nangi Lo)	Stampede (PI Geoff Sparrow)
<b>Metastatic - hormone sensitive</b>		CANC - 3947 - TITAN (PI Salvatore Natale)					
<b>Metastatic - hormone sensitive</b>			ENZAMET (PI Alastair Thomson)				
<b>Metastatic - castrate resistant</b>		CANC - 4225 Jansen study (PI Salvatore Natale)					
<b>Metastatic - castrate resistant</b>			CANC 4237 ARMOR3-SV (PI Duncan Wheatley)				
<b>Metastatic - castrate</b>					TOPARP (PI Mohini)		

Different methods of communication across the Network have been attempted

- Quarterly webinars (poor attendance)
- Interactive portfolio maps, live 12/2016
- ? Local news letter

# Portfolio Successes

- PHOTO trial – RD&E highest national recruiter
- RAIDER – TSFT second highest recruiter nationally
- STAMPEDE - recruitment, open at 5/7 acute sites
- STAR trial – 6 sites open, 3 over recruited, recognition that other 3 need to review targets to avoid ‘closing in red’
- UKGPCS – open and over recruited at all sites
- Add Aspirin – open all sites

# CRN: SWP Uro oncology

- Raising the profile of the CRN;SWP nationally
- Ensuring access to ‘bread and butter’ clinical trials e.g. STAMPEDE, STAR, ATLANTIS, RAMPART
- Working to balance the portfolio
- Opening the trials as they start to maximise recruitment
- Working towards at least one site running more competitive/ commercial clinical trials